iVAPS in treating COPD| ResMed
iVAPS in treating COPD

iVAPS in treating COPD

Improved gas exchange

ResMed’s Intelligent Volume Assured Pressure Support (iVAPS) therapy targets alveolar ventilation, improving gas exchange and reducing CO₂ levels in hypercapnic patients. Using advanced technology iVAPS combines the advantages of pressure support ventilation with the assurance of a target volume, maintaining alveolar ventilation even as a patient’s respiratory rate changes.

Studies have shown that iVAPS is as effective as high pressure NIV in increasing minute ventilation (MV) in obese patients with COPD.1

In another study iVAPS was more effective at reducing nocturnal  hypercapnia in COPD patients compared to high pressure NIV (p=0.003). There was also a trend towards more restful sleep at home for patients randomized to iVAPS compared to patients on high pressure NIV.2

Making expert titration easy

According to experts iVAPS might help to simplify the establishment of effective long‐term NIV in stable hypercapnic COPD patients because it uses a pre‐defined inspiratory pressure range that, unlike high pressure NIV, does not require titration of IPAP over several days.2

Another study also found that iVAPS can alleviate some of the complex time‐consuming elements that are required for effective setup of NIV therapy.3 The researchers concluded that “iVAPS is as effective as pressure support initiated by a skilled healthcare professional in controlling nocturnal hypoventilation.” It may facilitate NIV use without extensive prior team experience, they said in their study published in the European Respiratory Journal.

60 minutes more3

Another benefit of iVAPS is that it can help overcome the challenges involved in getting patients to stay on NIV therapy long‐term.

Evidence from a study demonstrated that patients treated with iVAPS for the first time adhered to therapy for 60 minutes longer (per session) compared to treatment using standard pressure support modes.3

The study concluded that iVAPS “may encourage adherence to therapy for patients newly adjusting to NIV”.3

Intelligent, automatic and personalized, this advanced technology with an intelligent back‐up rate (iBR) offers a smart choice for managing patients with chronic stable COPD.


  1. Ekkernkamp, E. et al. Minute ventilation during spontaneous breathing, high‐intensity Noninvasive positive pressure ventilation and intelligent volume assured pressure support in hypercapnic COPD. Journal of Chronic Obstructive Pulmonary Disease 2014; 11:52‐58. 
  2. Ekkernkamp, E. et al. Impact of intelligent volume‐assured pressure support on sleep quality in stable hypercapnic chronic obstructive pulmonary disease patients: a randomized, crossover study. Respiration 2014; published online. 
  3. Jaye J, Kelly J, et al. Eur Respir J 2012; 40: Suppl. 56, 519s.